Ranbaxy Laboratories (Ranbaxy) recently purchased the Provantis preclinical software suite developed by Instem, a leading provider of IT solutions to the global early development healthcare market, to automate laboratory processes at its R&D headquarters in Gurgaon, India.
Ranbaxy will be implementing Provantis 9, the latest version of Instem’s market leading preclinical software solution. A comprehensive suite of integrated Provantis modules will be deployed, including inlife, pathology, tables and statistics, clinical pathology, protocol and report assembly. Provantis will also enable in replacing in-house developed applications to streamline processes and further improve productivity, with a range of professional services purchased to facilitate quicker, smoother implementation and faster return on investment.
Provantis software has the potential to provide enhanced compliance capabilities while delivering demonstrable efficiency improvements to Ranbaxy at its Gurgaon R&D center , while also offering enhanced compliance capabilities, integrated reporting and reduced QC burden. Ranbaxy’s continued focus on research and development has resulted in several regulatory approvals in both developed and emerging markets, including the development of India’s first New Chemical Entity (NCE), Synriam, a new age cure for malaria.
According to Neil Donaldson, VP global sales, Europe and Asia, Instem, “We are delighted to welcome Ranbaxy as our newest client in the Asia Pacific region and look forward to a long and successful partnership. Instem recognises the increasingly important role that Indian organisations play in the global pharma market and we are committed to supporting the future growth and development of the Indian R&D community.”
Instem entered the early drug development market in India during 2005 when they welcomed their first Indian customer, Advinus Therapeutics. Instem maintains a physical presence in the region through its office in Pune.